Leonard M. Gralnik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leonard M. Gralnik has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Olga Lopez
Medicine, Florida International University, Herbert Wertheim College of Medicine, Miami, USA
2 shared publications Aditi Desai
1 shared publication- Adriana Foster
Florida International University, Miami, USA
1 shared publication - Ana Vila Irigoyen
Medicine, Florida International University, Herbert Wertheim College of Medicine, Miami, USA
1 shared publication Anna T. LaTray
1 shared publication- Armin Ghomeshi
Florida Int Univ, Urol, Herbert Wertheim Coll Med, Miami, FL 33199 USA
1 shared publication
Latest Publications
- Open Access
- 16 January 2024
- Published by Elsevier in Psychiatry Research Case Reports
- Vol. 3 (1)
Clearing the air: Multimodal treatment of a case of olfactory reference syndrome
- 16 January 2024
- Published by Elsevier in Psychiatry Research Case Reports
- Vol. 3 (1)
Open AccessClearing the air: Multimodal treatment of a case of olfactory reference syndrome
- 13 October 2023
- Published by Springer Nature
- p. 263-291
Psychopharmacologic Treatment of Psychiatric Disorders in First Responders
- 13 October 2023
- Published by Springer Nature
- p. 263-291
Psychopharmacologic Treatment of Psychiatric Disorders in First Responders
- Open Access
- 26 November 2022
- Published by Springer Nature in Cureus
- Vol. 14 (11) , e31905
Maintenance Electroconvulsive Therapy, Developmental Regression, Depression and Catatonia in an Adolescent With Down Syndrome: A Case Report
This is a case report involving a 22-year-old male with a past medical history of Down syndrome and major depressive disorder who, at age 16, became preoccupied with returning to an infant-like state. He experienced a gradual deterioration in his mood over a year and began to show symptoms consistent with catatonia. These symptoms included waxy flexibility, hypokinesis, decreased appetite, mutism, and altered sleep habits. Pharmacologic therapy was initiated, and the patient experienced a waxing and waning pattern of improvement and regression. Over several years, various combinations of antidepressants, benzodiazepines, and second-generation antipsychotics were attempted. The patient and his family discontinued all medications except his benzodiazepine in early 2019 and decided to try electroconvulsive therapy (ECT). After more than 100 sessions of ECT between 2019 and 2022, the patient showed notable improvement in overall mood, and his appetite and sleep completely returned to baseline. His speech, affect, and movement also improved. With ECT, the patient showed the most sustained and substantial improvement in his catatonic symptoms. ECT has been historically shown to improve these types of symptoms in catatonic patients, including those who have Down syndrome. Often, clinicians do not consider the possibility of catatonia in patients with this type of presentation, which is unfortunate as misdiagnosis leads to increased morbidity. Additionally, there has not been much discussion of the optimal length of treatment and the necessity of slowly tapered maintenance therapy in the literature. This case report illustrates how catatonia can be a major cause of developmental regression in patients with Down syndrome and offers an example of a promising management strategy for the treatment of this condition.
- 26 November 2022
- Published by Springer Nature in Cureus
- Vol. 14 (11) , e31905
Open AccessMaintenance Electroconvulsive Therapy, Developmental Regression, Depression and Catatonia in an Adolescent With Down Syndrome: A Case Report
This is a case report involving a 22-year-old male with a past medical history of Down syndrome and major depressive disorder who, at age 16, became preoccupied with returning to an infant-like state. He experienced a gradual deterioration in his mood over a year and began to show symptoms consistent with catatonia. These symptoms included waxy flexibility, hypokinesis, decreased appetite, mutism, and altered sleep habits. Pharmacologic therapy was initiated, and the patient experienced a waxing and waning pattern of improvement and regression. Over several years, various combinations of antidepressants, benzodiazepines, and second-generation antipsychotics were attempted. The patient and his family discontinued all medications except his benzodiazepine in early 2019 and decided to try electroconvulsive therapy (ECT). After more than 100 sessions of ECT between 2019 and 2022, the patient showed notable improvement in overall mood, and his appetite and sleep completely returned to baseline. His speech, affect, and movement also improved. With ECT, the patient showed the most sustained and substantial improvement in his catatonic symptoms. ECT has been historically shown to improve these types of symptoms in catatonic patients, including those who have Down syndrome. Often, clinicians do not consider the possibility of catatonia in patients with this type of presentation, which is unfortunate as misdiagnosis leads to increased morbidity. Additionally, there has not been much discussion of the optimal length of treatment and the necessity of slowly tapered maintenance therapy in the literature. This case report illustrates how catatonia can be a major cause of developmental regression in patients with Down syndrome and offers an example of a promising management strategy for the treatment of this condition.
- Open Access
- 19 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28199
Psychostimulants for the Treatment of Comorbid Post-traumatic Stress Disorder (PTSD) in a Patient With Attention-Deficit/Hyperactivity Disorder (ADHD): A Case Report and Literature Summary
We present a case of a 35-year-old female with an extensive history of attention-deficit/hyperactivity disorder (ADHD) who experienced a traumatic sexual and physical assault and later developed post-traumatic stress disorder (PTSD). The patient disclosed that her current medication (Vyvanse) used to treat ADHD has been the only treatment modality that has helped control her intrusive thoughts and nightmares. Decreased dopaminergic receptors are associated with developing PTSD and psychostimulants are known to have an effect of increasing Dopamine release. This case report shows promising results and potential off-label use of psychostimulants for the treatment of PTSD.
- 19 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28199
Open AccessPsychostimulants for the Treatment of Comorbid Post-traumatic Stress Disorder (PTSD) in a Patient With Attention-Deficit/Hyperactivity Disorder (ADHD): A Case Report and Literature Summary
We present a case of a 35-year-old female with an extensive history of attention-deficit/hyperactivity disorder (ADHD) who experienced a traumatic sexual and physical assault and later developed post-traumatic stress disorder (PTSD). The patient disclosed that her current medication (Vyvanse) used to treat ADHD has been the only treatment modality that has helped control her intrusive thoughts and nightmares. Decreased dopaminergic receptors are associated with developing PTSD and psychostimulants are known to have an effect of increasing Dopamine release. This case report shows promising results and potential off-label use of psychostimulants for the treatment of PTSD.
- Open Access
- 1 January 2020
- Published by Moscow State University of Psychology and Education in Clinical Psychology and Special Education
- Vol. 9 (3) , 105-126
Case Series of Transcranial Direct Current Stimulation as an Augmentation Strategy for Attention Bias Modification Treatment in Adolescents with Anxiety Disorders
This article presents the results of a case series to assess the feasibility, acceptability, and clinical promise of transcranial Direct Current Stimulation (tDCS) as an augmentation strategy in clinic referred adolescents. Attention Bias Modification Treatment (ABMT) is a computer-based attention-training protocol designed to reduce rapidly deployed attention orienting to threat and thereby reduce anxiety symptom severity. Studies of ABMT reveal overall small to medium effect sizes. Advances in the neural underpinnings of attention to threat and attention-training protocols suggest the potential of tDCS of the dorsolateral prefrontal cortex (dlPFC) as a novel augmentation strategy to enhance ABMT’s efficacy (ABMT + tDCS). However, tDCS has never been tested in a sample of adolescents with anxiety disorders. Six adolescents with a primary anxiety disorder completed all four ABMT + tDCS sessions. Adverse effects were mild and transient. Adolescents and parents independently reported fair to excellent levels of satisfaction. Impairment ratings of the primary anxiety disorder significantly decreased. Further, electrophysiological data recorded via electroencephalography (EEG) suggested decreases in neural resources allocated to threat. These findings support the feasibility, acceptability, and clinical promise of tDCS as an augmentation strategy in adolescents with anxiety disorders, and provide the impetus for further investigation using randomized controlled designs in larger samples.
- 1 January 2020
- Published by Moscow State University of Psychology and Education in Clinical Psychology and Special Education
- Vol. 9 (3) , 105-126
Open AccessCase Series of Transcranial Direct Current Stimulation as an Augmentation Strategy for Attention Bias Modification Treatment in Adolescents with Anxiety Disorders
This article presents the results of a case series to assess the feasibility, acceptability, and clinical promise of transcranial Direct Current Stimulation (tDCS) as an augmentation strategy in clinic referred adolescents. Attention Bias Modification Treatment (ABMT) is a computer-based attention-training protocol designed to reduce rapidly deployed attention orienting to threat and thereby reduce anxiety symptom severity. Studies of ABMT reveal overall small to medium effect sizes. Advances in the neural underpinnings of attention to threat and attention-training protocols suggest the potential of tDCS of the dorsolateral prefrontal cortex (dlPFC) as a novel augmentation strategy to enhance ABMT’s efficacy (ABMT + tDCS). However, tDCS has never been tested in a sample of adolescents with anxiety disorders. Six adolescents with a primary anxiety disorder completed all four ABMT + tDCS sessions. Adverse effects were mild and transient. Adolescents and parents independently reported fair to excellent levels of satisfaction. Impairment ratings of the primary anxiety disorder significantly decreased. Further, electrophysiological data recorded via electroencephalography (EEG) suggested decreases in neural resources allocated to threat. These findings support the feasibility, acceptability, and clinical promise of tDCS as an augmentation strategy in adolescents with anxiety disorders, and provide the impetus for further investigation using randomized controlled designs in larger samples.